The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Kazuaki Hashiguchi - Daiwa Securities Group Inc - Analyst
: Hashiguchi speaking. The first question is to Abe-san or Okuzawa-san. Fifth MTP 2021 announced as one of the objectives post DXd ADC
selection. That initiative, in today's presentation, how much is that reflected?
LSEG STREETEVENTS | www.lseg.com | Contact Us
consent of LSEG. 'LSEG' and the LSEG logo are registered trademarks of LSEG and its affiliated companies.
DECEMBER 15, 2025 / 10:30PM, 4568.T - Daiichi Sankyo Co Ltd Science and Technology Day
DXd ADC franchise I see that as a large backbone pillar just one of that rather than that with the various initiatives that you have introduced
today a sustainable growth you're going to achieve, is that the understanding?
Or within what you have introduced a post-ADC modality, what is expected as a major pillar, the franchise whether there's a possibility that,
that is included as well? So within what you have introduced the weight, the difference of weight, whether there are any or not, we would
like -- I would like you to comment, please.
Question: Kazuaki Hashiguchi - Daiwa Securities Group Inc - Analyst
: The second question is also the question directly to Abe-san. As you mentioned earlier, on page 25, new ADC 1, 2, 3, for these, the target,
for instance, had 2 or TROP02 like that, the conventional DXd ADC. It's the same as that but a further stronger efficacy safety targeted ones
are included or the first DXd ADC? The new targets that you were not able to obtain. And for those new patients, it's a kind of effort for you
to provide a treatment option, which is closer to what you are aiming at as a company?
|
